Temporal changes in the rate of progression to death among Italians with known date of HIV seroconversion: Estimates of the population effect of treatment

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 22, Issue 1, 1999, Pages 65-70

  Dorrucci, Maria ^a   Balducci, Maria ^a   Pezzotti, Patrizio ^a   Sinicco, Alessandro ^b   Alberici, Francesco ^c   Rezza, Giovanni ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b AMEDEO DI SAVOIA HOSPITAL   (Italy)

^c Dermatology Department   (Italy)

Author keywords

Antiretroviral therapy; Survival

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DEATH; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 0345411645     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199909010-00008     Document Type: Article

References (20)

1. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalisations in 10 French AIDS reference centres. AIDS 1997;11:F101-5.
2. Centers for Disease Control. Update: Trends in AIDS incidence, deaths, and prevalence - United States 1996. MMWR Morb Mortal Wkly Rep 1997;46:165-73.
3. Hogg RS, O'Shaughnessy, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals [letter]. Lancet 1997;349:1294.
4. Gebhardt M, Rickenbach M, Egger M, et al. Impact of antiretroviral combination therapies on AIDS surveillance report in Switzerland. AIDS 1998;12:1195-1201.
5. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348:283-91.
6. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
7. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997;315:1194-9.
8. Palella FJ, Delaney KM, Morman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
9. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998;352:1725-30.
10. Rezza G, Dorrucci M, Pezzotti P, Lazzarin A, Angarano G, Sinicco A, et al. The seroconversion study on the natural history of HIV infection. In: Nicolosi A, ed. HIV epidemiology: models and methods. New York: Raven Press, 1994:279-89.
11. Ancelle-Park R. Expanded European AIDS case definition. Lancet 1993;341-441.
12. Lee ET. Statistical Methods for Survival Data Analysis, 2nd ed. New York: John Wiley and Sons, 1992.
13. Pezzotti P, Napoli PA, Acciai S, et al. Increasing survival time after AIDS in Italy: the role of new combination antiretroviral therapies. AIDS 1999;13:249-55.
14. Phillips AN, Pezzotti P, Cozzi Lepri A, Rezza G. CD4 lymphocyte count as a determinant of the time from HIV seroconversion to AIDS and death from AIDS: evidence from the Italian Seroconversion Study. AIDS 1994;8:1299-305.
15. Detels R, Muñoz A, McFarlene G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 1998;280:1497-1503.
16. Colfax G, Vittinghoff E, Holmberg SD, Buchbinder S. Time to AIDS diagnosis increased in 1996, when use of highly active antiviral therapy (HAART) became prevalent [abstract 13307]. Presented at the XII World AIDS Conference, Geneva, 1998.
17. Hamilton JD, Hartigan MP, Simberkoff MS, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. N Engl J Med 1992;326: 437-43.
18. Glesby MI, Hoover DR. Survivor Treatment selection bias in observational studies: examples from the AIDS literature. Ann Intern Med 1996;124:999-1005.
19. Dorrucci M, Pezzotti P, Phillips AN, Alliegro MB, Rezza G. Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. AIDS 1997;11:461-7.
20. Lundgren JD, Phillips AN, Pedersen, et al. Comparison of longterm prognosis of patients with AIDS treated and not treated with zidovudine. JAMA 1994;271:1088-92.